New Hope for Multiple Sclerosis Patients

Multiple sclerosis patients often struggle with spasticity, a condition characterized by muscle stiffness and spasms. Researchers have been exploring alternative treatments to help alleviate these symptoms. One such treatment involves the use of intermittent negative pressure, or INP, applied to the lower limb.

In a recent study, patients with multiple sclerosis were randomly assigned to one of two groups: one receiving a low dose of INP (-10 mmHg) and the other receiving a high dose (-40 mmHg). The treatment was administered daily for four weeks using a device called FlowOx 2.0. The goal was to compare the effectiveness of these two different levels of INP on spasticity and pain.

Surprisingly, the results showed that both groups experienced significant improvements in spasticity and pain, with no notable difference between the two doses. Patients in both groups reported a decrease in muscle stiffness and pain, with the high-dose group showing a mean change of -1.6 in spasticity and -3.0 in pain. These findings suggest that INP treatment may be a useful non-pharmacological option for managing spasticity in multiple sclerosis patients.

The study also found that the treatment was well-tolerated, with high compliance rates and only mild to moderate device-related adverse events. While no improvements were observed in objective walking tests, the results still offer new hope for patients struggling with spasticity and pain. By providing a non-invasive and relatively safe treatment option, INP therapy could potentially improve the quality of life for thousands of people living with multiple sclerosis.

The use of INP therapy is a promising area of research, and further studies are needed to fully understand its potential benefits and limitations. For now, it represents a valuable addition to the range of treatment options available for multiple sclerosis patients. By continuing to explore innovative approaches like INP therapy, researchers may uncover new ways to manage symptoms and improve the lives of those affected by this complex condition.